What question did this study set out to answer?

To evaluate the efficacy of the PRMT5 inhibitor SCR-6920 in combination with anti-angiogenic therapy.

Abstract 5142: PRMT5 inhibitor SCR-6920 downregulates HIF-1α and exhibits synergistic antitumor activity with Bevacizumab

View Full Paper

Ask AI

Bookmark

Authors

The study demonstrates SCR-6920's synergistic antitumor effect with bevacizumab in ovarian cancer, indicating a novel treatment strategy.

To evaluate the efficacy of the PRMT5 inhibitor SCR-6920 in combination with anti-angiogenic therapy.
Characterization of SCR-6920's effects on HIF-1α/VEGF axis
Preclinical evaluation in cancer cell lines
Xenograft models for in vivo assessment
RNA-seq analysis to assess gene expression changes
SCR-6920 downregulated HIF-1α protein levels and reduced VEGF expression
Enhanced tumor growth suppression observed with SCR-6920 and bevacizumab
No increase in toxicity in the combination treatment
SCR-6920 showed additive effects with various standard chemotherapies

Yang et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

View Full Paper

Ask AI

Bookmark

Authors

The study demonstrates SCR-6920's synergistic antitumor effect with bevacizumab in ovarian cancer, indicating a novel treatment strategy.

To evaluate the efficacy of the PRMT5 inhibitor SCR-6920 in combination with anti-angiogenic therapy.
Characterization of SCR-6920's effects on HIF-1α/VEGF axis
Preclinical evaluation in cancer cell lines
Xenograft models for in vivo assessment
RNA-seq analysis to assess gene expression changes
SCR-6920 downregulated HIF-1α protein levels and reduced VEGF expression
Enhanced tumor growth suppression observed with SCR-6920 and bevacizumab
No increase in toxicity in the combination treatment
SCR-6920 showed additive effects with various standard chemotherapies

Yang et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark